About Hallux
Hallux is a company based in Laguna Hills (United States) founded in 2012 by Mark Taylor and Jay Birnbaum. Hallux has raised $27.2 million across 4 funding rounds from investors including OrthoArizona and Deerfield. Hallux offers products and services including Hallux Subungual Gel. Hallux operates in a competitive market with competitors including Scynexis, PolyPid, F2g, PanTher Therapeutics and Amplyx Pharmaceuticals, among others.
- Headquarter Laguna Hills, United States
- Founders Mark Taylor, Jay Birnbaum
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hallux Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$27.2 M (USD)
in 4 rounds
-
Latest Funding Round
$10.71 M (USD), Series B
Apr 26, 2023
-
Investors
OrthoArizona
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hallux
Hallux offers a comprehensive portfolio of products and services, including Hallux Subungual Gel.
Topical gel for treating onychomycosis via physician application.
People of Hallux
Unlock access to complete
Unlock access to complete
Funding Insights of Hallux
Hallux has successfully raised a total of $27.2M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $10.71 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hallux
Hallux has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include OrthoArizona and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Chain of orthopedic clinics
|
Locked | Locked | Locked |
Investor details for Hallux
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hallux
Investment portfolio details for Hallux
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hallux
Detailed financials for Hallux
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hallux Comparisons
Peer comparison for Hallux
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hallux
Hallux operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, PolyPid, F2g, PanTher Therapeutics and Amplyx Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| Locked | Locked | Locked |
Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API)
|
|
| Locked | Locked | Locked |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| Locked | Locked | Locked |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured.
|
Detailed competitors of Hallux
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hallux
Complete news archive for Hallux
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hallux
Hallux was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Hallux is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.
Mark Taylor is the current CEO of Hallux. They have also founded this company.
Hallux is a funded company, having raised a total of $27.2M across 4 funding rounds to date.
Hallux was founded in 2012 in Laguna Hills, United States, and operates in the pharmaceutical sector focused on fungal infection treatments. A biodegradable dosage form is developed for subungual administration of terbinafine hydrochloride, targeting nail infections directly. High concentrations of the antifungal agent are delivered selectively to infection sites, improving efficacy over traditional methods. Operations emphasize innovative routes for onychomycosis management.
Hallux's top competitors include PanTher Therapeutics, Scynexis and PolyPid.
Hallux offers Hallux Subungual Gel.
Hallux has 2 investors. Key investors include OrthoArizona, and Deerfield.